Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs TG Therapeutics, Inc.

Teva vs. TG Therapeutics: A Decade of Financial Strategy

__timestampTG Therapeutics, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014245186925078000000
Thursday, January 1, 2015198865804717000000
Friday, January 1, 2016126316895096000000
Sunday, January 1, 2017219779984986000000
Monday, January 1, 2018207590004214000000
Tuesday, January 1, 2019208380003806000000
Wednesday, January 1, 20201218120003671000000
Friday, January 1, 20211521370003528000000
Saturday, January 1, 2022832310003445000000
Sunday, January 1, 20231227060003498000000
Monday, January 1, 20243702000000
Loading chart...

Unlocking the unknown

A Tale of Two Pharmaceutical Giants: Teva vs. TG Therapeutics

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and TG Therapeutics, Inc. from 2014 to 2023. Over this period, Teva's SG&A expenses have shown a downward trend, decreasing by approximately 31% from 2014 to 2023. In contrast, TG Therapeutics experienced a significant rise, with expenses increasing nearly fivefold, peaking in 2021. This divergence highlights the contrasting strategies of these companies: Teva's focus on cost optimization versus TG Therapeutics' aggressive investment in growth. As the pharmaceutical landscape continues to shift, these financial insights provide a window into the strategic priorities of these industry leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025